IBRX Projected Dividend Yield
ImmunityBio Inc ( NASDAQ : IBRX )ImmunityBio is a clinical-stage biotechnology company developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. Co.'s platforms include: antibody cytokine fusion proteins, which include Anktiva™, a class of biopharmaceuticals that improve the therapeutic potential of cytokines, and promote lymphocyte infiltration at a site of disease, improving immune response; and DNA, RNA, and recombinant protein vaccine technologies, which are for infectious diseases to target key viruses, including coronavirus, and for oncology to deliver tumor-associated antigens, and neoepitopes (expressed only by cancer cells). 20 YEAR PERFORMANCE RESULTS |
IBRX Dividend History Detail IBRX Dividend News IBRX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |